| Literature DB >> 29923174 |
Irene Jiménez1,2,3,4, Mathieu Chicard1,2,3,4, Léo Colmet-Daage1,2,3,4, Nathalie Clément1,3,4, Adrien Danzon1,2,3,4, Eve Lapouble5, Gaelle Pierron5, Mylène Bohec6, Sylvain Baulande6, Dominique Berrebi7, Paul Fréneaux4,8, Aurore Coulomb9,10, Louise Galmiche-Rolland11, Sabine Sarnacki12,13, Georges Audry10,14, Pascale Philippe-Chomette15, Hervé J Brisse4,16, François Doz1,4,13, Jean Michon1,4, Olivier Delattre1,2,4, Gudrun Schleiermacher1,2,3,4.
Abstract
Circulating tumor DNA (ctDNA) is a powerful tool for the molecular characterization of cancer. The most frequent pediatric kidney tumors (KT) are Wilms' tumors (WT), but other diagnoses may occur. According to the SIOP strategy, in most countries pediatric KT have a presumptive diagnosis of WT if they are clinically and radiologically compatible. The histologic confirmation is established after post-chemotherapy nephrectomy. Thus, there is a risk for a small fraction of patients to receive neoadjuvant chemotherapy that is not adapted to the disease. The aim of this work is to perform molecular diagnosis of pediatric KT by tumor genetic characterization based on the analysis of ctDNA. We analyzed ctDNA extracted from plasma samples of 18 pediatric patients with KT by whole-exome sequencing and compared the results to their matched tumor and germline DNA. Copy number alterations (CNAs) and single nucleotide variations (SNVs) were analyzed. We were able to detect tumor cell specific genetic alterations-CNAs, SNVs or both-in ctDNA in all patients except in one (for whom the plasma sample was obtained long after nephrectomy). These results open the door to new applications for the study of ctDNA with regards to the molecular diagnosis of KT, with a possibility of its usefulness for adapting the treatment early after diagnosis, but also for disease monitoring and follow up.Entities:
Keywords: Kidney tumors; Pediatrics; Renal tumors; Wilms’ tumors; cell-free DNA; circulating tumor DNA
Mesh:
Substances:
Year: 2018 PMID: 29923174 DOI: 10.1002/ijc.31620
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396